Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blood Donor CVD 9000
NCT03724357Phase 4Terminated
- Sponsor
- University of Maryland, Baltimore
- Start
- Nov 2018
- Primary completion
- Oct 2021
- Modality
- Live Biotherapeutic Products, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of cholera vaccine, live, oral in cholera, sponsored by University of Maryland, Baltimore. Primary endpoints: Change in the Absolute Percentage of Positive CD4+ CD25+/OX40+ T Cells at Day 29 and Change in Absolute Percentage of Positive T Follicular/Helper 17 Cells Expressing CD154 at Day 29. Started Nov 2018; status: terminated.
02
Drugs
cholera vaccine, live, oral
03
Conditions
cholera
Beyond the preview
Go deeper on NCT03724357.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03724357.